Core Insights - Ascentage Pharma Group International is participating in the BTIG Virtual Biotechnology Conference on July 29-30, 2025, to engage with investors [1][2] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancers, with a strong pipeline of innovative drug candidates targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [3][6] Lead Assets - The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for treating patients with chronic myeloid leukemia (CML) with T315I mutations and is included in the China National Reimbursement Drug List [4] - The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor recently approved for treating relapsed and/or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in China, with multiple global registrational Phase III trials currently underway [5] Research and Development - Ascentage Pharma has established a robust R&D framework, securing global intellectual property rights and forming partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with prominent research institutions [6]
Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025